FDA approves Purdue's controversial OxyContin for kids aged 11 to 16

Purdue Pharma now has FDA permission to market highly controversial opioid painkiller OxyContin to an even younger population. Late last week, the agency green-lighted the drug in patients aged 11 to 16 who haven't benefited enough from alternative therapies. The warnings and precautions for pediatric patients are the same as those for adults, the FDA said. More

Suggested Articles

Move over, Roche. There’s a new small-cell lung cancer therapy on the scene, and it belongs to AstraZeneca.

Gilead CEO promised to make remdesivir affordable, shortly after the company backed off its request for orphan status amid a public backlash.

Weeks after launching a U.S. trial to evaluate IL-6 inhibitor Kevzara for COVID-19, Sanofi and Regeneron have launched a matching study abroad.